1. Home
  2. SWAG vs TPST Comparison

SWAG vs TPST Comparison

Compare SWAG & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stran & Company Inc.

SWAG

Stran & Company Inc.

HOLD

Current Price

$2.04

Market Cap

28.2M

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.79

Market Cap

26.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWAG
TPST
Founded
1994
2011
Country
United States
United States
Employees
156
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.2M
26.2M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
SWAG
TPST
Price
$2.04
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
66.7K
118.0K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$1.50
52 Week High
$3.50
$12.22

Technical Indicators

Market Signals
Indicator
SWAG
TPST
Relative Strength Index (RSI) 69.07 44.10
Support Level $1.61 $1.69
Resistance Level $2.23 $2.15
Average True Range (ATR) 0.13 0.11
MACD 0.03 -0.02
Stochastic Oscillator 85.54 8.97

Price Performance

Historical Comparison
SWAG
TPST

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: